Optimizing BCMA-directed therapies: Balancing efficacy, safety, and PROs

On March 5, 2026, the Multiple Myeloma Hub held a virtual symposium, titled Optimizing dosing of BCMA-directed therapies for improved quality of life in multiple myeloma. During the symposium, Hang Quach, St Vincent’s Hospital Melbourne and University of Melbourne, Melbourne, AU, delivered a presentation on optimizing dosing strategies for B-cell maturation antigen (BCMA)-directed therapies in multiple myeloma (MM). In this presentation, Quach discusses the importance of dose modification in the real-world use of BCMA-directed therapies and emphasizes the need to balance efficacy and safety with long-term quality of life (QoL). Quach outlines dosing strategies for belantamab mafodotin and bispecific antibodies, and shares key clinical and patient-reported outcome data demonstrating the impact of dose adaptation on toxicity and QoL.This independent educational activity was supported by GSK. All content was developed independently by SES in collaboration with the faculty. The funder was allowed no influence on the content of this activity.  Hosted on Acast. See acast.com/privacy for more information.